Protective effects of aliskiren in doxorubicin-induced acute cardiomyopathy in rats

Abstract

In this study, effect of aliskiren (ALK) on doxorubicin (DXR)-induced cardiomyopathy in rats was evaluated. ALK (50 and 100 mg/kg/day) was administered for 7 days and a single intraperitoneal injection of DXR (20 mg/kg) on day 5. The animals were sacrificed 48 h after DXR administration. DXR produced significant elevation in malondialdehyde (MDA) and significantly inhibited the activity of glutathione (GSH) in heart tissue, with a significant rise in the serum levels of lactate dehydrogenase (LDH), total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL) and reduction in high-density lipoprotein (HDL), indicating acute cardiac toxicity. ALK pretreatment significantly reduced the MDA concentration and ameliorated the inhibition of cardiac GSH activity. ALK also significantly improved the serum levels of LDH, TC, TG, LDL and reduction in HDL in DXR-treated rats. Furthermore, histological examination of the heart sections confirmed the myocardial injury with DXR administration and the near-normal pattern with ALK pretreatment. The results provide clear evidence that the ALK pretreatment offered significant protection against DXR-induced enzymatic changes and cardiac tissue damage.

Keywords

doxorubicin aliskiren cardiotoxicity renin inhibitor cardiomyopathy

References

Gianni L. , Salvatorelli E. , Minotti G. Anthracycline cardiotoxicity in breast cancer patients. Synergism with trastuzumab and taxanes. Cardiovasc Toxicol 2007; 7: 67-71.

Bryant J. , Picot J. , Levitt G. , Sullivan I. , Baxter L. , Clegg A. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review. Health Tech Assess 2007; 11: 1-102.

Kumar D. , Kirshenbaum LA , Danelisen I. , Singal PK Apoptosis in adriamycin cardiomyopathy and its modulation by probucol. Antioxid Redox Signal 2001; 3: 135-145.

Wallace KB Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis . Cardiovascular Toxicology 2007; 7: 101-107.

Sawyer DB , Fukazawa R. , Arstall MA Daunorubicininduced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane . Circ Res 1999; 84: 257-265.

Jensen BV , Nielsen SL , Jensen TS Angiotensinconverting enzyme inhibitor in the treatment of epirubicin-induced dilated cardiomyopathy. Ugeskr Laeger 1997 ; 159(13): 1945-1949.

Jensen BV , Nielsen SL , Skovsgaard T. Treatment with angiotensinconverting- enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet 1996; 347: 297-299.

Baker KM , Booz GW , Dostal DE Cardiac actions of angiotensin II: role of an intracardiac rennin-angiotensin system. Ann Rev Physiol 1992; 54: 227-241.

Dunn FG , Oigman W. , Ventura HO , Messeri FH , Kobrin I. , Frohlich ED Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol 1984; 53: 105-108.

10.

Gradman AH , Schmieder RE , Lins RL Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients . Circulation 2005; 111: 1012-1018.

11.

Kim S. , Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52: 11-34.

12.

Nussberger J. , Wuerzner G. , Jensen C. , Brunner HR Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril . Hypertension 2002; 39: E1-E8.

13.

Iqbal M. , Dubey K. , Anwer T. , Ashish A. , Pillai KK Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacol Rep 2008; 60: 382-390.

14.

Luft CF Achieving the goal of optimized renin system suppression: preclinical experience with a direct renin inhibitor. J Renin Angiotensin Aldosterone Sys 2006; 7: S12-S15.

15.

Lum G. , Gambino SR A comparison of serum versus heparinised plasma for routine chemistry tests . Am J Clin Pathol 1974; 61: 108.

16.

Wybenga DR , Pileggi VJ , Dirstine PH , Giorgio JD Direct manual determination of serum total cholesterol with a single stable reagent. Clin Chem 1970; 16: 980-984.

17.

Stein A. , Mayer GL National Cholesterol Education Program Recommendations for the Triglycerides Measurement: Executive Summary. Clin Chem 1995; 41: 1421-1426.

18.

Ohkawa H. , Oshishi N. , Yagi K. Assay for lipid peroxides in animal tissue by thiobarbituric acid reaction . Anal Biochem 1979; 95: 351-358.

19.

Lowry OH , Rosenburg NJ , Farr AL , Randall RJ Protein measurement with Folin phenol reagent. J Biol Chem 1951; 193: 265-275.

20.

Sedlack J. , Lindsay RH Estimation of total, protein bound and non-protein bound sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem 1968; 25: 192-205.

21.

Belur B. , Kandaswamy N. , Mukherjee KL Laboratory technology - a procedure manual for routine diagnostic tests. Delhi, India: Tata Mc Graw Hill Co. Ltd, 1990, p.1124-118.

22.

Steinherz LJ , Steinherz PG , Tan CC , Heller G. , Murphy L. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. J Am Med Assoc 1991; 266: 1672-1677.

23.

Myers CE The role of free radical damage in the genesis of doxorubicin cardiac toxicity . In: Muggia FM , Young CW , Carters K (eds.) Anthracycline antibiotics in cancer chemotherapy The Hague : Martinus Nijhoff, 1982, 297-305.

24.

Doroshow JH Effect of anthracycline antibiotics on oxygen free radical formation in rat heart. Cancer Res 1983; 43: 460-472.

25.

Singal PK , Deally CM , Weinberg LE Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol 1987; 19: 817-828.

26.

Yin X. , Wu H. , Chen Y. , Kang YJ Induction of antioxidants by adriamycin in mouse heart. Biochem Pharmacol 1998; 56: 87-93.

27.

Porta EA , Joun NS , Matsumura L. , Nakasone B. , Sablan H. Acute adriamycin cardiotoxicity in rats. Res Comm Chem Pathol Pharmacol 1983; 41: 125-137.

28.

Clement DL , De Buyzere ML , De Bacquer. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension . New Engl J Med 2003; 24: 2407-2415.

29.

Fleetwood G. , Boutinet S. , Meier M. , Wood JM Involvement of the renin-angiotensin system in ischemic damage and reperfusion arrhythmias in the isolated perfused rat heart. J Cardiovasc Pharmacol 1991; 17: 351-356.

30.

Li K. , Chen X. Protective effects of captopril and enalapril on myocardial ischemia and reperfusion damage of rat. J Mol Cell Cardiol 1987; 19: 909-915.

31.

Weber KT , Brilla CG Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin- aldosterone system. Circulation 1991; 83: 1849-1865.

32.

Buyukokuroglu ME , Taysi S. , Buyukavci M. , Bakan E. Prevention of acute adriamycin cardiotoxicity by dantrolene in rats. Hum Exp Toxicol 2004 ; 23: 251-256.

33.

Fadillioglu E. , Erodogen H. , Sogut S. , Kuku I. Protective effects of erdosteine against doxorubicin induced cardiomyopathy in rats. J Appl Toxicol 2003; 23: 71-74.

34.

Lefrak EA , Pitha J. , Rosenheim S. , Gottlieb JA A clinicopathologic analysis of adriamycin cardiotoxicity Cancer 1973; 32: 302-314.

35.

Siveski-Iliskovic N. , Hill M. , Chow DA Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 1995; 91: 10-15.

36.

Deepa PR , Varalakshmi P. Protective effect of low molecular weight heparin on oxidative injury and cellular abnormalities in adriamycin-induced cardiac and hepatic toxicity . Chem Biol Interact 2003; 146: 201-210.

37.

Singal PK , Iliskovic N. Doxorubicin-induced cardiomyopathy. New Engl J Med 1998; 339: 900-905.

38.

Myers CE , McGuire WP , Liss RH , Ifrim I. , Grotzinger K. , Young RC Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response . Science 1977; 197: 165-167.

39.

Saad SY , Najjar TA , Al-Rikabi AC The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol Res 2001; 43: 211-218.

40.

Yilmaz S. , Atessahin A. , Sahna E. , Karan I. , Ozers S. Protective effect of lycopen on adriamycin-induced cardiotoxicity, nephrotoxicity . Toxicology 2006; 218: 164-171.

41.

Dinesh M Parmar , Jadav SP Letter to the editor. Aliskiren: a novel renin inhibitor for hypertension. Ind J Physiol Pharmacol 2007; 51: 99-101.